Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.

@article{Inoue2000TreatmentOH,
  title={Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.},
  author={K Inoue and Joel W. Slaton and D W Davis and Daniel J. Hicklin and David James McConkey and T Karashima and Robert R Radinsky and C P Dinney},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2000},
  volume={6 7},
  pages={2635-43}
}
  • K Inoue, Joel W. Slaton, +5 authors C P Dinney
  • Published 2000 in
    Clinical cancer research : an official journal of…
Vascular endothelial cell growth factor (VEGF) regulates angiogenesis and metastasis of bladder cancer (transitional cell carcinoma, TCC) through binding to VEGF receptor-2 (VEGFR-2). In this study, we evaluated whether the anti-VEGFR monoclonal antibody (Mab) DC101 in combination with paclitaxel inhibited tumorigenesis, angiogenesis, and metastasis of human TCC growing within the bladder of athymic nude mice. In vivo therapy with Mab DC101 and paclitaxel induced significant regression of… CONTINUE READING